Scientists achieve efficient brain-targeted drug delivery

Fudan University School of Basic Medicine Zhan Changyou team designed a novel brain-targeted liposome drug, in the blood circulation process can accurately "fish" the endogenetic lipoprotein and maintain its biological activity, to achieve efficient brain-targeted drug delivery. Recently, the relevant research results published online in Nature - Communication.
lipids are the most widely used nano-drug vectors in clinical practice. Targeted liposome drugs are functional molecules (such as small molecules, peptides and antibodies) modified on the surface of lipids in order to break through the physiological barriers in the drug delivery process, such as blood-brain barriers, blood-eye barriers and biofilm barriers, to achieve drug accumulation at the target site, thereby improving efficacy and reducing toxic side effects. The research related to target lipid drugs has been very active in the past 40 years, but it has not yet achieved clinical transformation, and it is urgent to adjust the idea from the source design.
There are a variety of lipoproteins in the plasma that can cross the blood-brain barrier, and one of the removal mechanisms of the A-beta protein in the brain is to transfer to the outer week by binding lipid binding regions of a variety of lipoproteins, while exposing the binding regions of the subjects, which are transported to the outer week by the corresponding subjectivity on the blood-brain barrier. Because the relevant subject can be transported in both directions, the exosome can also be transported to the brain.
researchers bionic A-beta protein design to obtain non-toxic short peptides, modified on the surface of the lipid body, in the blood circulation process actively adsorption of the target lipoprotein lipid binding area, while exposing the subject binding area to the lipid surface, play an efficient brain targeting role. After the target short peptide modified lipid-carrying anti-tumor drug ammycin, a variety of in-place brain tumors (cerebroglioma and myeloma) were successfully treated, which significantly prolonged the median survival of model mice.
This brain-targeted drug delivery strategy breaks through the traditional design idea, actively uses functional proteins in plasma, overcomes many defects of traditional brain-targeted liposome drugs, and has high safety and good prospects for clinical transformation, and the research results have been applied for relevant international patents. This delivery strategy has a similar function in human blood and can be applied to nano-delivery systems other than liposomes. (Source: Huang Xin, China Science Journal)
relevant paper information: